Hormonal treatment for prostate cancer

Bibliography

• GREENLEE RT, MURRAY T, BOLDEN S et al.: Cancer statis-tics 2000. CA Cancerj Clin. (2000) 50(1):7–33.
   PubMed Web of Science ®Google Scholar
• GITTES R: Carcinoma of the prostate. N. Engl. J. Med. (1991) 324:236–245.
   PubMed Web of Science ®Google Scholar
• •A concise overview of prostate cancer epidemiology, natural history and treatment.
   Google Scholar
• CABOT A: The question of castration for enlarged prostate. Ann. Surg (1896) 24:265.
   PubMedGoogle Scholar
• WHITE J: The present position of the surgery of the hypertrophied prostate. Ann. Surg (1893) 18:152.
   PubMedGoogle Scholar
• HUGGINS C, HODGES C: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. (1941) 1:293–297.
   Google Scholar
• HUGGINS C, STEVENS R, HODGES C: Studies on prostatic carcinoma: II. The effect of castration on advanced carcinoma of the prostate gland. Arch. Surg (1941) 43:209–233.
   Google Scholar
• THE LEUPROLIDE STUDY GROUP: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N. Engl. J. Med (1984) 311:1281–1286.
   PubMed Web of Science ®Google Scholar
• SCHELLHAMMER P: Combined androgen blockade for the treatment of metastatic carcinoma of the prostate. Ural (1996) 47:622–628.
   Google Scholar
• VERMEULEN A: The androgens In: Hormones in Blood, Grey C, James V (Eds.) Academic Press, London, UK (1979).
   Google Scholar
• KYPRIANOU N, ISAACS J: Activation of pr ogr ammed cell death in the rat ventral prostate after castration. Endocrinology (1988) 122:552–562.
   PubMed Web of Science ®Google Scholar
• BYAR D, CORLE D: Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. Natl. Cancer Inst. Monogr. (1988) 7:165–170.
   Google Scholar
• VETERANS ADMINISTRATION CO-OPERATIVE UROLOGIC RESEARCH GROUP: Treatment and survival of patients with cancer of the prostate. Surg. Gynecol. Obstet. (1967) 124:1011–1017.
   PubMedGoogle Scholar
• BYAR D: The Veterans Administration CooperativeUrological Research Group's studies of cancer of the prostate. Cancer (1973) 32:1126–1130.
   PubMed Web of Science ®Google Scholar
• CITRIN D, KIES MS, WALLEMARK CB et al.: A Phase IIstudy of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer. Cancer (1985) 56:457–460.
   PubMed Web of Science ®Google Scholar
• FUCHS S, LUNDANES E, LEBAN J, FOLKERS K, BOWERS C:On the existence and separation of the follicle stimulating hormone releasing hormone from the luteinizing hormone releasing hormone. Biochem. Biophys. Res. Commun. (1979) 88:92–96.
   PubMed Web of Science ®Google Scholar
• LINDE R, DOELLE GC, ALEXANDER N et al.: Reversibleinhibition of testicular steroidogenesis and spermato-genesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N. Engl. J. Med (1981) 305:663–667.
   PubMed Web of Science ®Google Scholar
• EMTAGE LA, TRETHOWAN C, HILTON C, KELLY K, BLACKLEDGE GR: Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbe-strol 3 mg/day in advanced prostate cancer. Am. J. Clin. Oncol. (1988) 11 (Suppl. 2):173–175.
   Google Scholar
• KLIOZE S, MILLER M, SPIRO T: A randomized, compara-tive study of buserelin with DES/orchiectomy in the treatment of stage D2 prostatic cancer patients. Am. J Clin. Oncol. (1988) 2 (Suppl.):S5176–S5182.
   Google Scholar
• DEBRUYNE FM, DENIS L, LUNGLMAYER G et al.: Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma. J Ural. (1988) 140:775–777.
   PubMed Web of Science ®Google Scholar
• KAISARY AV, TYRRELL CJ, PEELING WB, GRIFFITHS K: Comparison of LII-RH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br. J Ural. (1991) 67:502–508.
   PubMedGoogle Scholar
• BREWSTER S, GILLATT D: Advanced prostate cancer: what's new in hormonal manipulation? Br. J Hosp. Med. (1993) 49:710–715.
   Web of Science ®Google Scholar
• BRUCHOVSKY N, GOLDENBERG SL, AKAKURA K, RENNIEPS: Luteinizing hormone-releasing hormone agonists in prostate cancer. Cancer (1993) 72:1685–1691.
   PubMed Web of Science ®Google Scholar
• DIJKMAN GA, DEBRUYNE FM, FERNANDEZ DEL MORAL Pet al.: A randomised trial comparing the safety and efficacy of the zoladex 10.8 mg depot, administered every 12 weeks to that of the zoladex 3.6 mg depot, administered every 4 weeks, in patients with advanced prostate cancer. Eur. Ural. (1995) 27:43–46.
   Google Scholar
• DIJKMAN GA, DEBRUYNE FM, FERNANDEZ DEL MORAL Pet al.: Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogues in the treatment of metastatic carcinoma of the prostate. ELIE Ural. (1986) 12:400–402.
   Google Scholar
• LABRIE F, DUPONT A, BELANGER A, LACHANCE R et al.:Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. j Ural. (1987) 138:804–806.
   PubMed Web of Science ®Google Scholar
• KUHN JM, BILLEBAUD T, NAVRATIL H et al.: Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostate carcinoma by administration of an antian-drogen (nilutamide). N. Engl. J. Med. (1989) 321:413–418.
   PubMed Web of Science ®Google Scholar
• CAMPION M, KUCA B, GARNICK M: The magnitude of lupr on (L) or zoladex (Z) testosterone (I) and luteinizing hormone (LH) surge is dependent on formulation: comparative results of L and Z vs. abarelix-depot (A-D), a GnR.11 antagonist devoid of androgen surge. Proc. Am. Soc. Clin. Oncol. (1999) 18:320a. One of the initial reports on the new LHRH antagonist, Abarelix.
   Google Scholar
• GARNICK MB, TOMERA K, CAMPION M, KUCA B, GEFTER M: Abarelix-depot (A-D), a sustained-release (SR) formulation of a potent GnR1-1 pure antagonist in patients (pts) with prostate cancer (PrCA): Phase II clinical results and endocrine comparison with superagonists lupron (L) and zoladex (2). Proc. Am. Soc. Clin. Oncol. (1999) 18:321a.
   Google Scholar
• •One of the initial reports on the new HRH antagonist, Abarelix.
   Google Scholar
• DECENSI AU, BOCCARDO F, GUARNERI D et al.:Monotherapy with nilutamide, a pure nonsteroidal antiandrogen in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J. Ural. (1991) 146:377–381.
   Google Scholar
• KAISARY A: Current clinical studies with a newnonsteroidal antiandrogen, casodex. Prostate (1994) 5:27–33.
   PubMedGoogle Scholar
• BURTON S, TRACHTENBERG J: Effectiveness of antian-drogens in the rat. J. Urol. (1986) 136:932–935.
   PubMedGoogle Scholar
• WYSOWSKI DK, FREIMAN JP, TOURTELOT JB, HORTON ML: Fatal and nonfatal hepatotoxicity associated with flutamide. Ann. Intern. Med. (1993) 118:860–864.
   PubMed Web of Science ®Google Scholar
• WYSOWSKI D, FOURCROY D: Flutamidehepatotoxicity. J. Ural. (1996) 155:209–212.
   PubMedGoogle Scholar
• TYRRELL C: Casodex: a pure non-steroidal antian-drogen used as monotherapy in advanced prostate cancer. Prostate (1992) 4 (suppl.) 97–104.
   Google Scholar
• KAISARY A, KLARSKOVM P, MCKILLOP D: Absence ofhepatic enzyme induction in prostate cancer patients receiving `Casodex' (bicalutamide). Anticancer Drugs (1996) 7:54–59.
   PubMed Web of Science ®Google Scholar
• SCHELLHAMMER P, SHARIFI R, BLOCK N et al.: Maximalandrogen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalu-tamide (Casodex) versus flutamide, each in combina-tion with luteinizing hormone releasing hormone analogue therapy. Urology (1996) 47 (Stipp'. a):54–60.
   Google Scholar
• CRAWFORD E, SMITH J, SOLOWAY M: A randomizedcontrolled clinical trial of leuprolide and Anandron versus leuprolide and placebo for advanced prostate cancer. J. Ural. (1990) 143:221A.
   Google Scholar
• BOCCARDO F, DECENSI AU, GUARNERI D et al.:Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study. Cancer Detect. Prey. (1991) 15:501–503.
   PubMedGoogle Scholar
• JACOBO E, SCHMIDT JD, WEINSTEIN SH et al.: Comparison of flutamide (SCH-13521) and diethylstil-bestrol in untreated advanced prostatic cancer. Urology (1976) 8:231–233.
   PubMedGoogle Scholar
• SOGANI P, WHITMORE W: Experience with flutamide in previously untreated patients with advanced prostatic cancer. J Ural. (1979) 122:640–643.
   PubMed Web of Science ®Google Scholar
• CHANG A, YEAP B, DAVIS T et al.: Double-blind, randomized study of primary hormonal treatment of stage 132 prostate carcinoma: flutamide versus diethyl-stilbestrol. J Clin. Oncol. (1996) 1 4 (8):2250–2257.
   Google Scholar
• CHODAK G, SHARIFI R, KASIMIS B et al.: Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology (1995) 46:849–855.
   PubMed Web of Science ®Google Scholar
• BALES G, CHODAK G: A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology (1996) 47(Suppl. 1A):38–43.
   Google Scholar
• TYRRELL CJ, KAISARY AV, IVERSEN Petal.: A randomised comparison of `Casodex" (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur. Urol. (1998) 33:447–456.
   Google Scholar
• IVERSEN P, TYRRELL CJ, KAISARY AV et al.: Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology (1998) 51:389–396.
   PubMed Web of Science ®Google Scholar
• SCHER HI, LIEBERTZ C, KELLY WK etal.: Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J. Clin. Oncol. (1997) 15:2928–2938.
   Google Scholar
• BOCCARDO F, RUBAGOTTI A, BARICHELLO M et al.: Bicalutamide monotherapy versus flutamide pls goserelin in prostate cancer patients: results of an Italian prostate cancer project study. J. Clin. Oncol. (1999) 17(7):2027–2038.
   PubMed Web of Science ®Google Scholar
• JOYCE R, FENTON MA, RODE P et al.: High-dose bicaluta-mide for androgen-independent prostate cancer: effect of prior hormonal therapy. J. Ural. (1998) 159:149–153.
   PubMed Web of Science ®Google Scholar
• DE VOOGT HJ, SMITH PH, PAVONE-MACALUSO M et al.: Cardiovascular side effects of diethylstilbestrol, cyproteerone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762.1 Ural. (1986) 1 3 5:303–307.
   Google Scholar
• GOLDENBERG S, BRUCHOVSKY N: Use of cyproterone acetate in prostate cancer. Um/ Clin. North. Am. (1991) 18:111–122.
   PubMed Web of Science ®Google Scholar
• GELLER J, ALBERT J, YEN S: Treatment of advanced cancer of the prostate with megestrol acetate. Urology (1978) 12:537–541.
   PubMedGoogle Scholar
• GELLER J: Megestrol acetate plus low-dose estrogen in the management of advanced prostatic carcinoma. Ural. Clin. North Am. (1991) 18:83–91.
   PubMed Web of Science ®Google Scholar
• BONOMI P, PESSIS D, BUNTING N et al.: Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer. Semin. Oncol. (1985)12 (Stipp'. 1):36–39.
   Google Scholar
• JOHNSON DE, BABAIAN RJ, SWANSON DA et al.: Medical castration using megestrol acetate and minidose estrogen. Urology (1988) 31:371–374.
   PubMed Web of Science ®Google Scholar
• VENNER PM, KLOTZ PG, KLOTZ LH et al.: Megestrol acetate plus minidose diethylstilbestrol in the treatment of carcinoma of the prostate. Setnin. Oncol (1988) 1 5 (Suppl. 1):62–67.
   Google Scholar
• HUGGINS C, SCOTT W: Bilateral adrenalectomy in prostatic cancer. Ann. Surg (1945) 122:1031–1041.
   Web of Science ®Google Scholar
• BRACCI U: Antiandrogens in the treatment of prostatic cancer. Eur.j Ural. (1979) 5:303–306.
   PubMed Web of Science ®Google Scholar
• LABRIE F, DUPONT A, BELANGER A etal.: New hormonal therapy in prostatic carcinoma: combined treatment with anagonist and an antiandrogen. Clin.Invest. Med. (1982) 5:267–275.
   Google Scholar
• CRAWFORD ED, EISENBERGER MA, MCLEOD DG et al.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J Med (1989) 321:419–424.
   PubMed Web of Science ®Google Scholar
• ••A large NCI Intergroup study randomising patients toreceive leuprolide plus placebo or leuprolide plus flutamide, which demonstrated that CAB was superior to monotherapy in terms of time to progression and survival. Men with minimal metastatic disease derived the most benefit from CAB.
   Google Scholar
• DENTS EL CARNELRO DE MOURA JL, BONO A et al.: Goserelin acetate and flutamide versus bilateral orchiectomy: a Phase III EORTC trial (30853). Urology (1993) 42:119–130.
   PubMed Web of Science ®Google Scholar
• •EORTC trial comparing goserelin plus flutamide to orchiec-tomy. Confirmed the NCI Intergroup study results showing CAB was superior in terms of time to progression and survival.
   Google Scholar
• JANKNEGT RA, ABBOU CC, BARTOLETTI R et al: Orchiec- tomy and nilutamide or placebo as treatment of metastatic prostate cancer in a multi-center double- blind randomized trial. J. Urol. (1993) 149:77–83.
   PubMed Web of Science ®Google Scholar
• •Compared orchiectomy plus nilutamide to orchiectomy plus placebo and confirmed the NCI Intergroup results that CAB is superior in terms of time to progression.
   Google Scholar
• EISENBERGER MA, BLUMENSTEIN BA, CRAWFORD ED et al.: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J Med. (1998) 339:1036–1042.
   PubMed Web of Science ®Google Scholar
• ••A large randomised study of orchiectomy ± flutamide whichfailed to demonstrate an advantage to CAB. However, because an anti-androgen was frequently added at the time of progression in the control arm, this study may really address the timing (early versus late) of anti-androgen therapy.
   Google Scholar
• FOWLER JE JR, PANDEY P, SEAVER LE, FELIZ TP: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J. UroL (1995) 154:448–453.
   PubMed Web of Science ®Google Scholar
• •Delineates the utility of deferred flutamide treatment after gonadal androgen ablation.
   Google Scholar
• BERTAGNA C, DE GERY A, HUCHER M, FRANCOIS JP, ZANIRATO J: Efficacy of the combination of nilutamide and orchiectomy in patients with metastatic prostate cancer. Br. J. Ural (1994) 73(396–402).
   PubMedGoogle Scholar
• ••One of three meta-analyses attempting to define the benefitof CAB. A statistically significant 16% reduction in risk of progression was seen, while the 10% reduction in risk of death was not significant.
   Google Scholar
• DEBRUYNE FMJ, DE GERY A, HUCHER M, GODFROID N: Maximum androgen blockade with nilutamide combined with orchidectomy in advanced prostate cancer: an updated metaanalysis of 7 randomized, placebo-controlled trials (1191 patients). Eur. Ural. (1996) 30 (Stipp'. 2):264.
   Google Scholar
• •An update of the meta-analysis of Bertagna et al. comparing orchiectomy to orchiectomy plus nilutamide. The reduction in risk of progression with CAB remained significant.
   Google Scholar
• PROSTATE CANCER TRIALIST'S COLLABORATIVE GROUP: Maximal androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet (1995) 346:265–269.
   Google Scholar
• ••Large meta-analysis comparing castration alone to CAB. Nobenefit of CAB over monotherapy was seen. However, this study has been criticised for methodological flaws.
   Google Scholar
• LABRIE F, CRAWFORD D: Anti-androgens in treatment of prostate cancer (letter). Lancet (1995) 346:1031.
   PubMed Web of Science ®Google Scholar
• QUARTEY P: Anti-androgens in treatment of prostate cancer (letter). Lancet (1995) 346:1031.
   PubMed Web of Science ®Google Scholar
• WAXMAN J, PANDHA H: Anti-androgens in treatment of prostate cancer (letter). Lancet (1995) 346:1030.
   PubMedGoogle Scholar
• PROSTATE CANCER TRIALIST'S COLLABORATIVE GROUP: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet (2000) 355:1491–1498.
   Google Scholar
• ••Large meta-analysis comparing castration alone to CAB.Found that CAB added only a marginal survival benefit of 0-5% at five years.
   Google Scholar
• NOBLE R: Hormonal control of growth and progres-sion in tumors of Nb rats and a theory of action. Cancer. Res. (1977) 37:82–94.
   PubMed Web of Science ®Google Scholar
• BRUCHOVSKY N, RENNIE PS, COLDMAN AJ, GOLDEN-BERG SL, TO M, LAWSON D: Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. (1990) 50:2275–2282.
   PubMed Web of Science ®Google Scholar
• AKAKURA K, BRUCHOVSKY N, GOLDENBERG SL, RENNIE PS, BUCKLEY AR, SULLIVAN LD: Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate specific antigen. Cancer (1993) 71:2782–2790.
   PubMed Web of Science ®Google Scholar
• KLOTZ LH, HERR HW, MORSE MJ, WHITMORE WF JR: Intermittent endocrine therapy for advanced prostate cancer. Cancer (1986) 58:2546–2550.
   PubMed Web of Science ®Google Scholar
• HIGANO CS, ELLIS W, RUSSELL K, LANGE PH: Intermit-tent androgen suppression with leuprolide and flutamide for prostate cancer. Urology. (1996) 48:800–804.
   PubMed Web of Science ®Google Scholar
• BALES GT, SINNER MD, KIM JH, CHODAK GW: Impact of intermittent androgen deprivation on quality of life (Q0L). Proc. Am. Ural. Assoc. (1996) 155:578A.
   Google Scholar
• HIGANO C, STEPHENS C, NELSON P: Prospective serial measurements of bone mineral density (BMD) in prostate cancer patients without bone metastases treated with intermittent androgen suppression (IAS). Proc. Am. Soc. Clin. Oncol. (1999) 18:314a.
   Google Scholar
• HORWICH A, HUDDART R, GADD J: A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br. J. Ural. (1998) 81:96–99.
   PubMedGoogle Scholar
• GROSSFELD G, SMALL E, CARROLL P: Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology. (1998) 51:137–144.
   PubMed Web of Science ®Google Scholar
• KUREK R, RENNEBERG H, LUBBEN G, KIENLE E, TUNN UVV: Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur. Urol. (1999) 35 (Stipp'. 1):27–31.
   Google Scholar
• RITTMASTER R: Finasteride. N. Engl. J. Med. (1994) 33 0:120–125.
   Google Scholar
• MCCONNELL JD, WILSON JD, GEORGE FW, GELLER J, PAPPAS F, STONER E: Finasteride, an inhibitor of 5-alpha reductase, suppresses prostatic dihydrotestos-terone in men with benign prostatic hyperplasia. Clin. Endocrinol. Metab. (1992) 74:505–508.
   Google Scholar
• RITTMASTER RS, NORMAN RW, THOMAS LN, ROWDEN G: Evidence for atrophy and apoptosis in the prostates of men given finasteride. J. Clin. Endocrinol. Metab. (1996) 81:814–819.
   PubMed Web of Science ®Google Scholar
• GORMLEY GJ, STONER E, BRUSKEWITZ RC et al.: The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med. (1992) 327:1185–1191.
   PubMed Web of Science ®Google Scholar
• LAMB JC, LEVY MA, JOHNSON RK, ISAACS JT: Response of rat and human prostatic cancers to the novel 5-alpha reductase inhibitor, SK&F 105657. Prostate (1992) 21:15–34.
   PubMed Web of Science ®Google Scholar
• PRESTI JC JR, FAIR WR, ANDRIOLE G et al.: Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J. Urol. (1992) 148:1201–1204.
   PubMed Web of Science ®Google Scholar
• ANDRIOLE G, LIEBER M, SMITH J et al.: Treatment with finasteride following radical prostatectomy for prostate cancer. Urology (1995) 45:491–497.
   PubMed Web of Science ®Google Scholar
• FLESHNER N, TRACHTENBERG J: Sequential adrogen blockade: a biological study in the inhibition of prostatic growth. J. Um/ (1992) 148:1928–1931.
   Google Scholar
• ORNSTEIN DK, RAO GS, JOHNSON B, CHARLTON ET, ANDRIOLE GL: Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology (1996) 48:901–905.
   PubMed Web of Science ®Google Scholar
• BRUFSKY A, FONTAINE-ROTHE P, BERLANE K et al.: Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarci-noma of the prostate. Urology (1997) 49:913–920.
   PubMed Web of Science ®Google Scholar
• FLESHNER N, TRACHTENBERG J: Combination finaste-ride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol. (1995) 1 5 4:1642–1646.
   Google Scholar
• •The first report of peripheral androgen blockade utilising finasteride in combination with flutamide.
   Google Scholar
• ORNSTEIN D, SMITH D, ANDRIOLE G: Biochemicalresponse to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed. Urology (1998) 52:1094–1097.
   PubMed Web of Science ®Google Scholar
• STRUM S, SCHOLZ M, MCDERMED J: Intermittentandrogen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Oncologist (2000) 5:45–52.
   PubMedGoogle Scholar
• CHEN X, HAN R: Effect of glycyrrhetinic acid on DNAdamage and unscheduled DNA synthesis induced by benzo(alpha)pyrene. Chin. Med. Sci. J (1995) 10:16–19.
   PubMedGoogle Scholar
• SATO K, MOCHIZUKI M, SAIKI I: Inhibition of tumorangiogenesis and metastasis by saponin of Panax ginseng, ginsenoside-Rb2. Biol. Pharm. Bull. Tokyo (1994) 17:635–639.
   PubMed Web of Science ®Google Scholar
• WANG G, ZHANG J, MISUNO T: Antitumor active polysaccharides from the Chinese mushroom songshan lingzhi, the fruiting body of Ganoderma tsugae. Biosci. Biotechnol. Biochem. (1993) 57:894–900.
   PubMed Web of Science ®Google Scholar
• TANAKA S, KOK K, KINO K: Complete amino acid sequence of an immumodulatory protein, ling Thi-8: an immunomodulator from a fungus, Gan oderma lucidum, having similarity to immunoglobulin variable regions. J Biol. Chem. (1989) 264:16272–16377.
   Google Scholar
• AUSTINE C, PATEL S, ONO K: Site-specific DNA cleavageby mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. Biochem. (1992) 282:883–889.
   Google Scholar
• HSIEH T, CHEN SS, WANG X, WU JM: Regulation ofandrogen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LISICaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES. Biochem. Mol. Biol. Int. (1997) 42:535–544.
   PubMedGoogle Scholar
• KUBOTA T, HISATAKE J, HISATAKE Y et al.: PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo. Prostate (2000) 42:163–171.
   PubMed Web of Science ®Google Scholar
• TIWARI RK, GELIEBTER J, GARIKAPATY VP, YEDAVELLI SP, CHEN S, MITTELMAN A: Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer. In. Oncol. (1999) 14:713–719.
   Web of Science ®Google Scholar
• DIPAOLA RS, ZHANG H, LAMBERT GH et al.: Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N. Engl. J Med. (1998) 33 9:785–791.
   Google Scholar
• MOYAD M, PIENTA K, MONTIE J: Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease. Um/ (1999) 54:319–324.
   Google Scholar
• SMALL EJ, FROHLICH MW, BOK R et al.: Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J. Clin. Oncol. (2000) 18:3595–3603.
   PubMed Web of Science ®Google Scholar
• REESE D, SMALL E: Secondary hormonal manipulations in hormone refractory prostate cancer. Urol. Clin. N. Am. (1999) 26:311–321.
   PubMed Web of Science ®Google Scholar
• KELLY W, SCHER H: Prostate specific antigen decline after antiandrogen withdrawal. J. Urol. (1993) 149:607–609.
   PubMed Web of Science ®Google Scholar
• SMALL E, CARROLL P: Prostate-specific antigen decline after Casodex withdrawal: evidence for an antian-drogen withdrawal syndrome. Urology (1994) 43:408–410.
   PubMed Web of Science ®Google Scholar
• GOMELLA L, ISMAIL M, NATHAN F: Antiandrogen withdrawal syndrome with nilutamide. J. Ural. (1997) 157:1366.
   PubMed Web of Science ®Google Scholar
• HUAN S, GERRIDZEN R, YAU J: Antiandrogen withdrawal syndrome with nilutamide. Urology (1997) 49:632–634.
   PubMed Web of Science ®Google Scholar
• DAWSON N, MCLEOD D: Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J. Ural. (1995) 153:1946–1947.
   PubMed Web of Science ®Google Scholar
• AKAKURA K, AKIMOTO S, OHKI T: Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadi-none acetate. Urology (1995) 4:700–704.
   Google Scholar
• BISSADE N, KACZMAREK A: Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbesterol. J. Ural. (1995) 153:1944–1945.
   PubMed Web of Science ®Google Scholar
• SCHER H, LIEBERTZ C, KELLY W: Bicalutamide for advanced prostate cancer: the natural history versus treated history of disease. J. Clin. Oncol (1997) 15:2928–2938.
   PubMed Web of Science ®Google Scholar
• EASTHAM J, SARTOR 0: Isalutamide response after flutamide failure in postorchiectomy progressive prostate cancer. J Urol. (1998) 159:990.
   PubMed Web of Science ®Google Scholar
• SARTOR 0, COOPER M, WEINBERGER M etal.: Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of 'hormone--refractory' prostate cancer. J Natl. Cancer. Inst. (1994) 86:222–227.
   Google Scholar
• FIGG W, DAWSON N, MIDDLEMAN M: Flutamide withdrawal and concomitant initiation of aminoglu-tethimide in patients with hormone refractory prostate cancer. Acta Oncol. (1996) 35:295–298.
   Google Scholar
• DAWSON N, FIGG W, BRAWLEY 0: Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. Clin. Cancer. Res. (1998) 4:37–44.
   PubMed Web of Science ®Google Scholar
• JOHNSON D, BABAIAN R, VON ESCHENBACH A: Ketoconazole therapy for hormonally refractive metastatic prostate cancer. Urology (1988) 31:132–134.
   PubMed Web of Science ®Google Scholar
• SMALL EJ, BARON AD, FIPPIN L, APODACA D: Ketocona-zole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J. Ural. (1997) 157:1204–1207.
   PubMed Web of Science ®Google Scholar
• SMALL E, BARON A, BOK R: Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer (1997) 00:1755–1759.
   Google Scholar
• TANNOCK I, GOSPODAROWICZ M, MEAKIN W: Treatment of metastatic prostate cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin. Oncol. (1989) 7:590–597.
   PubMed Web of Science ®Google Scholar
• TANNOCK I, OSABA D, STOCKLER M: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliave end points. J. Clin. Oncol. (1996) 14:1756–1764.
   PubMed Web of Science ®Google Scholar
• KELLY W, CURLEY T, LEIBERTZ C: Prospective evalua-tion of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J. Clin. Oncol. (1995) 13:2208–2213.
   PubMed Web of Science ®Google Scholar
• STORLIE JA, BUCKNER JC, WISEMAN GA, BURCH PA, HARTMANN LC, RICHARDSON RL: Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer (1995) 76:96–100.
   PubMed Web of Science ®Google Scholar
• PATEL SR, KVOLS LK, HAHN RG, WINDSCHITL H, LEVITT R, THERNEAU T: A Phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate. Cancer (1990) 66:655;–658.
   Google Scholar
• CROMBIE C, RAGHAVAN D, PAGE J et al.: Phase II study of megestrol acetate for metastatic carcinoma of the prostate. Br. J. Urol. (1987) 59:443–446.
   PubMedGoogle Scholar
• DAWSON N, et al.: Megestrol acetate (MA) in men with hormone-refractory prostate cancer (HRPC): Prostate specific antigen (PSA) response and antiandrogen withdrawal (AAWD): Cancer and Leukemia Group B (CALGB) 9181. Proc. Am. Soc. Clin. Oncol. (1996) 15:241.
   Google Scholar
• OSBORN J, SMITH D, TRUMP D: Megestrol acetate in the treatment of hormone refractory prostate cancer. Am. Clin. Oncol. (1997) 20:308–310.
   PubMed Web of Science ®Google Scholar
• STRUM SB, MCDERMED JE, SCHOLZ MC, JOHNSON H, TISMAN G et al.: Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormonal blockade. Br. J. Urol. (1997) 79:933–941.
   PubMedGoogle Scholar
• DANIELL H: Osteoporosis after orchiectomy for prostate cancer. J. Urol. 1997. 157:439–444.
   PubMed Web of Science ®Google Scholar
• JACOBO E, SCHMIDT JD, WEINSTEIN SH et al.: Comparison of flutamide (SCH-13521) and diethylstil-bestrol in untreated advanced prostate cancer. Urology (1976) 8:231–233.
   PubMedGoogle Scholar
• SOGANI P, VAGAIWALA M, WHITMORE W: Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer (1984) 54:744–750.
   PubMed Web of Science ®Google Scholar
• MCFARLANE J, TOLLEY D: Flutamide therapy for advanced prostatic cancer: a Phase II study. Br. J Ural. (1985) 57:172–174.
   PubMedGoogle Scholar
• LUNDGREN R: Flutamide as primary treatment for metastatic prostatic cancer. Br. J. Urol. (1987) 59:156–158.
   PubMedGoogle Scholar
• LUND F, RASMUSSEN F: Flutamide versus stilboestrol in the management of advanced prostatic cancer: a controlled prospective study. Br. J. Ural. (1988) 61:140–142.
   PubMedGoogle Scholar
• PROUT GR JR, KEATING MA, GRIFFIN PP, SCHIFF SF: long-term experience with flutamide in patients with prostatic carcinoma. Urology (1989) 34 (Suppl.):37–45.
   Google Scholar
• DELAERE K, VAN THILLO E: Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin. Oncol. (1991) 18(5 Suppl. 6):13–18.
   Google Scholar
• IVERSEN P: Update of monotherapy trials with the new anti-androgen casodex (ICI 176,334). Eur. Ural. (1994) 26 (Suppl. 1):5–9.
   Google Scholar
• SOLOWAY MS, SCHELLHAMMER PF, SMITH JA JR, CHODAK GW, VOGELZANG NJ, KENNEALEY GT: Bicalu-tamide in the treatment of advanced prostatic carcinoma: a Phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy. j Urol. (1995) 154:2110–2114.
   PubMed Web of Science ®Google Scholar
• BELAND G, ELHILALI M, FRADET Y et al.: Total androgen ablation: Canadian experience. Ural. Clin. North. Am. (1991) 18:75–82.
   PubMed Web of Science ®Google Scholar
• TYRRELL CJ, ALTWEIN JE, KLIPPEL F et al.: A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer.]: Um/ (1991)146:1321–1326.
   Google Scholar
• MARSHALL V, THOMPSON D, RAGHAVAN D: First report of Australian multicenter randomized prostate cancer trial: flutamide does not add to the effect of orchiec-tomy for metastatic prostate cancer. Proc. Am. Assoc. Cancer. Res. (1992) 33:220.
   Google Scholar
• BOCCARDO F, PACE M, RUBAGOTTI A et al.: Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group. Eur. J. Cancer. (1993) 29A:1088–1093.
   PubMed Web of Science ®Google Scholar
• IVERSEN P, CHRISTENSEN M, FRITS E: A Phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer (1990) 66:1058–1066.
   PubMed Web of Science ®Google Scholar
• IVERSEN P, RASMUSSEN F, KLARSKOV P, CHRISTENSEN IJ: Long-term results of Danish prostatic cancer group trial 86: goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer. Cancer (1993) 72(33851–3854).
   Google Scholar
• BRUCHOVSKY N, KLOTZ LH, SADAR M et al.: Intermit-tent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology (1995) 45:839–844.
   PubMed Web of Science ®Google Scholar
• OLIVER RT, WILLIAMS G, PARIS AM et al.: Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology (1997) 49:79–82.
   PubMed Web of Science ®Google Scholar
• GLEAVE M, BRUCHOVSKY N, GOLDENBERG SL, RENNIE P et al.: Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Eur. Ural. (1998) 34 (Suppl. 3):37–41.
   Google Scholar
• •The largest reported series utilising IAD.
   Google Scholar
• THEYER G, HAMILTON G: Current status of intermittent androgen suppression in the treatment of prostate cancer. Urology (1998) 52:353–359.
   PubMed Web of Science ®Google Scholar
• CROOK JM, SZUMACHER E, MALONE S, HUAN S, SEGAL R: Intermittent androgen suppression in the manage-ment of prostate cancer. Urology (1999) 53:530–534.
   PubMed Web of Science ®Google Scholar